Antibody Drug Cost-Effective For Allergic Asthma, University of Washington and Novartis Pharma AG Study
Reuters Health -- The antibody drug omalizumab (Xolair) is cost-effective for treating allergic asthma that has not responded fully to steroid inhalers and other mediations, according to a report in the journal Allergy.